The present invention provides engineered human interleukin-1 beta antibodies, cells and vectors comprising DNA encoding the same, and methods for producing the antibodies. In addition, the present invention provides the use of the human engineered interleukin-1-beta antibodies for the treatment of inflammatory disease, such as cardiovascular disease and cancer.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
2.
PROCESS TO MAKE GLP1 RA AND INTERMEDIATES THEREFOR
The present invention relates to the synthesis of 3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo [4,3-c] pyridine-5-carbonyl] indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one, or a salt thereof, and related synthetic intermediate compounds.
Methods of treating Hand Eczema with baricitinib, including formulations and dose regimens. The amount of baricitinib may be administered as a 4 mg tablet or pill that includes one or more excipients. The amount of baricitinib may be administered daily or at some other frequency.
Solid forms of compound of (2R)-1-[4-[(R)-amino(5-chloro-2-hydroxy-4-methylphenyl)methyl]piperidin-1-yl]-2,3-dihydroxypropan-1-one are described. The solid form may be a pharmaceutically acceptable salt of the compound. The salt may be a carboxylic acid salt, such as a benzoic acid salt, a cinnamic acid salt, or a glutaric acid salt. Pharmaceutical compositions comprising the same and method of using the same in treating a condition such as psoriasis, rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, atopic dermatitis, and alopecia areata are also described.
C07D 211/26 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A computing device is provided having a processor in communication with a memory configured to store machine-readable instructions. The processor can access data indicative of times of a plurality of healthcare visits of the patient over time during an observation period, determine a metric based on the times of the plurality of healthcare visits of the patient over time during the observation period, and identify a patient for inclusion in the clinical trial when the metric exceeds a metric threshold.
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
10.
PIPERIDINE, MORPHOLINE AND TETRAHYDRO-PYRIDAZINE COMPOUNDS WITH LP(A) LOWERING ACTIVITY
The present disclosure provides compounds of the formula: and their pharmaceutically acceptable salts, and compounds of the formula: and their pharmaceutically acceptable salts, as well as pharmaceutical compositions comprising these compounds and their use in the treatment of cardiovascular disease and elevated Lp(a) plasma levels.
C07D 211/34 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 265/30 - 1,4-OxazinesHydrogenated 1,4-oxazines not condensed with other rings
C07D 417/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61K 31/4465 - Non-condensed piperidines, e.g. piperocaine only substituted in position 4
The present disclosure provides compounds of the formula: and their pharmaceutically acceptable salts, and compounds of the formula: and their pharmaceutically acceptable salts, as well as pharmaceutical compositions comprising these compounds and their use in the treatment of cardiovascular disease and elevated Lp(a) plasma levels.
C07D 211/62 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 9/00 - Drugs for disorders of the cardiovascular system
12.
ROOT CAUSE ANALYSIS FOR MACHINES IN MANUFACTURING NETWORK
A method for managing a manufacturing network comprises: first status information over a time period for a first machine and second status information over the time period for a second machine of the manufacturing network are obtained; the first status information comprises a first waiting event and the second status information comprises one or more stopped events; a dynamic time warping operation estimates, for a first set of time intervals within the time period associated with the first machine, a matching second set of time intervals associated with the second machine; based on determining whether a matching time interval that matches a time interval corresponding to a waiting event at the first machine corresponds to a stopped event at the second machine, the method includes indicating the second machine as a root cause of the waiting event of the first machine.
The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
The present invention generally relates to the treatment of ulcerative colitis with an anti-IL-23p19 antibody, in particular dosage regimens for the treatment of the disease.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 9/00 - Medicinal preparations characterised by special physical form
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
The present disclosure provides compounds of the formula: and their pharmaceutically acceptable salts, as well as pharmaceutical compositions comprising these compounds and their use in the treatment of cardiovascular disease and elevated Lp(a) plasma levels.
A61P 9/00 - Drugs for disorders of the cardiovascular system
C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
16.
PYRROLIDINE COMPOUNDS WITH Lp(a) LOWERING ACTIVITY
The present disclosure provides compounds of the formula: and their pharmaceutically acceptable salts, and compounds of the formula: and their pharmaceutically acceptable salts, as well as pharmaceutical compositions comprising these compounds and their use in the treatment of cardiovascular disease and elevated Lp(a) plasma levels.
C07D 207/08 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
C07D 209/46 - Iso-indolesHydrogenated iso-indoles with an oxygen atom in position 1
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/423 - Oxazoles condensed with carbocyclic rings
17.
LONG-ACTING AMYLIN RECEPTOR AGONISTS AND USES THEREOF
The present disclosure relates to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity and/or chronic weight management, dyslipidemia and/or NASH. The disclosure relates to compounds that agonize the amylin receptor and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity, and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment, prevention and/or diagnosis of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease; Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment, prevention and/or diagnosis of dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, hearing loss, heart failure, inflammation and inflammatory diseases and disorders inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders; Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment, prevention and/or diagnosis of metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and vascular diseases; pharmaceutical preparations.
19.
PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE
The embodiments of present invention provide processes and an intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide hemisuccinate, and formulations and product forms made by these processes. The embodiments of the present invention further provide for the preparation of lasmiditan acetate, 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide acetate salt, and/or pharmaceutical compositions thereof, and/or uses of lasmiditan acetate and formulations thereof in subcutaneous drug delivery.
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Product development; Pharmaceutical products development; Biological development services; Research and development services; Pharmaceutical drug development services; Scientific research and development; Analysis and evaluation of product development; Scientific research consulting; Research and development in the field of biotechnology; Research and development in the pharmaceutical and biotechnology fields; Providing information relating to scientific research in the fields of biochemistry and biotechnology; Compiling and analyzing data for research purposes in the field of medical science and pharmaceutical drug development; Compiling and analyzing data for training of artificial intelligence for use in the field of medical science and pharmaceutical drug development. Providing medical support; Medical information; Medical analysis services.
36 - Financial, insurance and real estate services
Goods & Services
Venture capital financing; venture capital services, namely, providing financing to seed and early-stage companies; Venture capital advisory, financing, funding and fund management services.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmacy services; online retail pharmacy services; mail order pharmacy services; online retail store services featuring pharmaceuticals; online retail pharmacy services for the ordering, purchase, and delivery of pharmaceuticals; pharmaceutical services, namely, processing prescription orders Housemark for a full line of pharmaceutical preparations Healthcare services; medical services; telemedicine services; arranging and providing medical information services relating to pharmaceuticals, namely, providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals
Described herein are preserved formulations of insulin-Fc fusions. The formulations include insulin-Fc fusions having prolonged pharmacokinetic and pharmacodynamic profiles sufficient for once weekly administration in the treatment of diabetes and are sufficiently stable to allow for storage and use without unacceptable loss of chemical or physical stability.
The present disclosure relates to methods and systems for predicting changes in a target physiological parameter of a target patient expected to result from a medication to be administered to the target patient. The methods and systems may comprise deriving one or more parameter-estimation functions based on historical data, wherein each parameter-estimation function models how a separate parameter of a prediction function varies in accordance with one or more starting physiological parameters. The methods and systems may further comprise receiving user input indicative of a value for one or more starting physiological parameters for the target patient, calculating a value for each parameter of the prediction function by applying the derived parameter-estimation functions to the one or more indicated values, and predicting changes in the target physiological parameter using the prediction function and the calculated parameter values. The predicted changes may then be displayed on a user-interface.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
31.
THERAPEUTIC USES AND DOSES OF LP(A) DISRUPTER COMPOUNDS
Once-daily, oral doses of the Lp(a) disrupter compound (2S)-3-[3-[[bis[[3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl]methyl]amino]methyl]phenyl]-2-[(3R)-pyrrolidin-3-yl]propanoic acid, or a pharmaceutically acceptable salt thereof, to be used in the treatment of cardiovascular disease, elevated Lp(a) levels, individuals with elevated Lp(a) levels at risk for cardiovascular events and atherosclerotic cardiovascular disease.
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
32.
DOSAGE REGIMENS FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES USING LY3871801
Disclosed herein are methods of treating a subject having an autoimmune or inflammatory disease, and formulations associated therewith, comprising administering to the patient a compound of (S)-5-benzyl-N-(7-(3-hydroxy-3-methylbut-1-yn-1-yl)-5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide, or a pharmaceutically acceptable salt thereof, wherein the compound or the pharmaceutically acceptable salt is administered at a dose of about 12.5 mg to about 125 mg free base equivalent of said compound per dose.
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 9/00 - Medicinal preparations characterised by special physical form
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 37/00 - Drugs for immunological or allergic disorders
33.
TREATMENT OR PREVENTION OF NEW-ONSET TYPE 1 DIABETES WITH BARICITINIB
The present invention provides methods of treating or preventing new-onset type 1 diabetes with baricitinib, either alone or in combination with insulin, insulin analogues and/or other immunomodulatory agent.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 9/00 - Medicinal preparations characterised by special physical form
Provided herein are methods and uses of antibodies against ELR+CXC chemokines for the treatment of hidradenitis suppurativa. Also provided are doses and dosing regimens for the methods and uses of antibodies against ELR+CXC chemokines for the treatment of hidradenitis suppurativa.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 39/00 - Medicinal preparations containing antigens or antibodies
One or more needle assemblies for a fluid delivery device includes a needle support that includes a connector coupler having various manufacturing methods to form a leak-tight seal around the needle. A flexible connector has a connector bore forming a fluid path in fluid communication with a bore of the needle. A driven member is disposed at least partially in the housing and driven to move the needle support(s) to move between a compact configuration, in which fluid may not be transferred through the needle, and an extended configuration, in which fluid may be transferred through the needle. A movable carousel can move the selected needle assembly of many to the activated position for fluid or drug delivery.
A61M 5/24 - Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or cartridges, e.g. automatic
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
36.
COMPOUNDS FOR THE DELIVERY OF GRANULIN ACROSS THE BLOOD BRAIN BARRIER
Compounds for the delivery of progranulin, a progranulin fragment, and/or at least one granulin protein subunit across the blood brain barrier. Compounds for the delivery of progranulin, a progranulin fragment, and/or at least one granulin protein subunit across the blood brain barrier, the compounds including a progranulin domain, a TfR1 binding domain, and optionally an albumin binding domain. Compounds for the delivery of wildtype or unmodified progranulin across the blood brain barrier.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present disclosure provides nectin-4 antibody drug conjugates and pharmaceutical compositions thereof, and methods of using for the treatment of cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The techniques described herein relate to computerized methods and apparatuses for detecting defects in manufactured components. In some embodiments, a system for monitoring for manufacturing defects may include an image capturing device configured to capture an image of a manufactured component. The system may compute a set of birth and death coordinates for each topological feature of a plurality of topological features in the image; determine a digital feature based on the computed sets of birth and death coordinates for each topological feature of the plurality of topological features; and determine, based on the digital feature, whether the image is indicative of a defect in the manufactured component. The sets of birth and death coordinates may be computed using topological data analysis. The digital feature may be used to determine whether the image is indicative of a defect in the manufactured component using a statistical model.
A medication delivery device is provided having a device body and a dose setting member attached to the device body and rotatable relative to the device body about an axis of rotation during dose setting or dose delivery. The medication delivery device further includes a sensor comprising a light source pointed in a first direction for emitting sensing light during dose setting or dose delivery, and a light sensor pointed in a second direction for receiving the sensing light during dose setting or dose delivery, wherein the light source is disposed with respect to the light sensor so that the first direction is angled with respect to the second direction. The medication delivery device further includes an electronics assembly in communication with the light sensor to determine data indicative of dosing information of the medication delivery device based on reception of the sensed light by the light sensor.
The present disclosure relates to a medication delivery device including a stabilizing apparatus for effective delivery of a dose of medication without interference with various device components or misapplication of pressure to the device by a user. The stabilizing apparatus couples to the medication delivery device and facilitates proper force delivery to the underlaying medication delivery device.
A Solid Phase Peptide Synthesis (SPPS) device and method of using the same for manufacturing peptides is taught herein. The system comprises at least two reactors, each reactor including a quantity of SPPS resin. The reactors are positioned in series. A de-protecting agent is added to the first reactor and then transferred to the second and third reactors, in series, thereby operating to de-protect the protected N-group. Wash solvent is added to the first reactor and then transferred to the second and this operation repeated several times. Likewise, an amino acid activated ester solution is added, in series, to the first, second and third reactors, thereby operating to couple the amino acid to the de-protected N-group. Wash solvent is added to the first reactor and then transferred to the second and this operation repeated several times prior to the next cycle. The use of the reactors in series reduces the overall solvent required. Online LCMS is also used to monitor progress and identity of reactions happening within the solid phase resin particles.
The present invention provides new intermediates and processes useful in the manufacture of tirzepatide, or a pharmaceutically acceptable salt thereof.
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
45.
CDK4 AND 6 INHIBITOR IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN PATIENTS PREVIOUSLY TREATED WITH A CDK4 AND 6 INHIBITOR
Disclosed are methods, uses, and combinations for treating hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HIER2−) advanced or metastatic breast cancer in patients previously treated with a CDK4 and 6 inhibitor, the methods, uses, and combinations including the administration of a CDK4 and 6 inhibitor in combination with fulvestrant. The methods uses and combinations may include a CDK4 and 6 inhibitor such as palbociclib, ribociclib, or abemaciclib with fulvestrant.
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Engineered antibody compounds and conjugates thereof, are provided, said antibody compounds and conjugates thereof are useful as agents for cancer immunotherapy. Engineered antibody compounds may include one or more amino acid residue substitutions within the constant regions of the antibody engineered into a parental antibody. Amino acid residue substitutions may include substitution of cysteine or alanine.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
The present invention relates to therapeutic compounds, novel RNA interference (RNAi) agents, that decrease expression of the Voltage-Gated Sodium Channel Alpha Subunit 10 (SCN10A) gene, which encodes a subunit of the Nav 1.8 or Nav 1.8 sodium channel. Such RNAi agents decrease levels of intact Nav 1.8 sodium channels and are useful in the treatment of diseases involving the regulation of SCN10A expression and function, such as chronic pain.
48.
MEDICATION DELIVERY SYSTEMS AND METHODS INCLUDING INJECTION SITE DETERMINATION AND TRACKING
A medication delivery system includes a housing and a medication delivery assembly carried by the housing. The medication delivery assembly delivers a medication to an injection site of a subject via an injection aperture. An ultrasound transducer is carried by the housing proximate to the injection aperture. The ultrasound transducer emits ultrasound waves into tissue of the subject at the injection site and receives reflected ultrasound waves from the tissue of the subject. A processor determines whether the reflected ultrasound waves indicate the presence of bone in the tissue of the subject. (1) When bone is present in the tissue, the processor determines that the injection site is located at an appendage of the subject; and (2) the processor otherwise determines that the injection site is located at an abdomen of the subject.
Methods and systems are provided for evaluating injection sites on a body of a patient. The methods/systems may instruct a patient to place one or more capacitance sensors in contact with a potential injection site on the body of the patient. The methods/systems may also comprise using a processing circuit to receive data indicative of a capacitance of body tissue at the potential injection site, as measured by the one or more capacitance sensors. The methods/systems may also comprise generating, using the processing circuit, an indication of a level of pain that would be expected to be experienced by the patient from a potential injection at the potential injection site based on the received capacitance.
The present invention provides novel intermediates and processes useful in the manufacture of tirzepatide, or a pharmaceutically acceptable salt thereof.
C07C 233/47 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
C07C 271/22 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
C07K 1/113 - General processes for the preparation of peptides by chemical modification of precursor peptides without change of the primary structure
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
The present invention provides compounds and methods targeting human lymphotactins, including therapeutic antibodies, pharmaceutical compositions and methods of use thereof, useful in the field of immune-mediated diseases including ulcerative colitis, vitiligo, multiple sclerosis, alopecia areata, psoriasis, type 1 diabetes, and asthma.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
52.
ANTI-IL-23P19 ANTIBODY REGULATION OF GENES INVOLVED IN BOWEL URGENCY IN ULCERATIVE COLITIS
The present disclosure is generally relates to methods of treating ulcerative colitis. The methods are particularly suitable for treating bowel urgency a specific sub-group of patients with ulcerative colitis and having bowel urgency.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
The present invention provides methods of treating or preventing new-onset type 1 diabetes with baricitinib, either alone or in combination with insulin, insulin analogues and/or other immunomodulatory agent.
The present invention provides compounds and methods targeting human lymphotactins, including therapeutic antibodies, pharmaceutical compositions and methods of use thereof, useful in the field of immune-mediated diseases including ulcerative colitis, vitiligo, multiple sclerosis, alopecia areata, psoriasis, type 1 diabetes, and asthma.
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A method is provided for presenting information from a particular medication delivery device to a user. The method includes: receiving a set of advertising packets, the set of advertising packets comprising at least one advertising packet from one or more medication delivery devices, the one or more medication delivery devices including the particular medication delivery device, wherein each advertising packet includes an identifier associated with a respective medication delivery device of the one or more medication delivery devices; determining a number of unique identifiers included in the set of advertising packets to determine a number of transmitting medication delivery devices; determining, based on the number of transmitting medication delivery devices, whether to prompt the user to provide identification information for the particular medication delivery device; and presenting the information from the particular medication delivery device to the user.
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
G16H 40/40 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A therapeutic agent delivery device includes a disposable portion and a reusable portion that detachably carries the disposable portion. The reusable portion includes a drive mechanism having a guide, a rotary actuator, and a follower drivably coupled to the rotary actuator and movably coupled to the guide. The rotary actuator is actuatable to rotatably drive the follower, and the follower thereby follows the guide and translates the drive mechanism. The drive mechanism thereby translates a syringe assembly of the disposable portion from a stowed configuration to a deployed configuration.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
61.
IMLUNESTRANT OR SALTS THEREOF FOR USE IN TREATING AND PREVENTING CENTRAL NERVOUS SYSTEM (CNS) METASTASES IN SUBJECTS HAVING ER+ BREAST CANCER
The disclosure provides compositions and methods comprising imlunestrant of a pharmaceutically acceptable salt thereof for the treatment and prevention of brain metastasis. The disclosure provides, within such compositions and methods, for the treatment and/or the prevention of brain metastases in a subject suffering from ER+ breast cancer.
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4741 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61P 35/04 - Antineoplastic agents specific for metastasis
Systems and methods facilitate sensing and tallying defecation events of subjects, such as participants in clinical trials for treatments for treating digestive diseases, such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and chronic constipation. Systems and methods may also be used by individual patients for sensing and tallying defecation events, and resulting data may be reviewed by a healthcare provider when evaluating patient gastrointestinal health and/or treatments.
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
63.
OLIGONUCLEOTIDE SYNTHESIS USING CYCLIC-PHOSPHOROUS NUCLEOSIDES
The present disclosure provides methods for preparing oligonucleotides. In certain embodiments, the present disclosure provides methods for preparing oligonucleotides using cyclic- phosphorous nucleosides. In certain embodiments, the present disclosure provides methods for preparing oligonucleotides using substituted benzyl alcohol nucleophiles. In certain embodiments, the present disclosure provides methods for preparing oligonucleotides using cyclic-phosphorous nucleosides and substituted benzyl alcohol nucleophiles.
C07H 1/00 - Processes for the preparation of sugar derivatives
C07H 19/11 - Pyrimidine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
The present invention provides compounds of the formula:
The present invention provides compounds of the formula:
The present invention provides compounds of the formula:
wherein A, Z, G, R1, R2, and R4 are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
66.
BISPECIFIC ANTI-FLT3/CD3 ANTIBODIES AND METHODS OF USE
Provided herein are bispecific anti-FLT3/CD3 antibodies and antigen binding fragments thereof, such as the antibodies and fragments that specifically bind human FLT3 and human CD3. In some aspects, provided herein are optimized humanized, bispecific anti-FLT3/CD3 antibodies and antigen binding fragments thereof, optionally, having certain amino acid substitutions that confer advantageous properties (e.g., optimal antigen binding, manufacturability and/or half-life properties). Also provided herein are pharmaceutical compositions comprising such antibodies or fragments. Also provided herein are methods of use of such antibodies and fragments.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 35/02 - Antineoplastic agents specific for leukemia
The present invention provides novel intermediates and processes useful in the manufacture of tirzepatide, or a pharmaceutically acceptable salt thereof.
C07C 233/47 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
C07C 271/22 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
C07K 1/113 - General processes for the preparation of peptides by chemical modification of precursor peptides without change of the primary structure
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
Methods are described for concentrating a biomolecule-containing solution, such as an oligonucleotide-containing solution, to a concentration ≥ about 200 mg/mL from an initial concentration of about ≤ 20 mg/mL, via thin film evaporation (TFE), for high dose/low volume applications. Apparatuses also are described for concentrating a biomolecule-containing solution as described herein.
In an embodiment, the present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof, and methods of using this compound for treating type II diabetes mellitus.
In an embodiment, the present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof, and methods of using this compound for treating type II diabetes mellitus.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/529 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
The present invention provides compounds of the formula:
The present invention provides compounds of the formula:
wherein A, Z, G, R1, R2, and R4 are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/537 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A therapeutic agent delivery device includes a disposable portion and a reusable portion that detachably carries the disposable portion. The reusable portion includes a drive mechanism having a guide, a rotary actuator, and a follower drivably coupled to the rotary actuator and movably coupled to the guide. The rotary actuator is actuatable to rotatably drive the follower, and the follower thereby follows the guide and translates the drive mechanism. The drive mechanism thereby translates a syringe assembly of the disposable portion from a stowed configuration to a deployed configuration.
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
The invention relates to reagents for in vivo imaging and detection of cancers that express platelet derived growth factor receptor alpha (PDGFR-alpha) using an olaratumab antibody, and methods of use thereof including methods for imaging cancers and methods for selecting patients for treatment.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
G01N 33/534 - Production of labelled immunochemicals with radioactive label
76.
REAGENTS AND METHODS FOR IMAGING CANCERS EXPRESSING PDGFRALPHA
The invention relates to reagents for in vivo imaging and detection of cancers that express platelet derived growth factor receptor alpha (PDGFRalpha) using an olaratumab antibody, and methods of use thereof including methods for imaging cancers and methods for selecting patients for treatment.
The invention relates to compositions comprising an olaratumab antibody conjugated to a therapeutic radioisotope, for treatment of cancers that express platelet derived growth factor receptor alpha (PDGFR- alpha), and methods of use thereof.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
78.
MEDICATION DELIVERY DEVICE WITH GEAR SET DOSAGE SYSTEM
A medication delivery device is disclosed including a rack-and-pinion plunger drive system. The drive system includes an output drive having a pawled end movably coupled with the ratchet teeth of the plunger, and a pinion drive coupled between the housing, the output drive and an actuator. Actuator is longitudinally movable between dose set and delivery positions. Movement of the actuator causes rotation of the pinion drive along the rack to translate the output drive member with the pawled end that is engaged with the plunger ratchet teeth to distally advance the plunger. The device may include one or more of an end of dose mechanism to limit travel of the actuator, a load brake system to stop travel of the plunger under high input forces, a dose detection system, and a dose selector to vary the amount of dose set.
The invention relates to compositions comprising an olaratumab antibody conjugated to a therapeutic radioisotope, for treatment of cancers that express platelet derived growth factor receptor alpha (PDGFR-alpha), and methods of use thereof.
A61P 35/04 - Antineoplastic agents specific for metastasis
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Educational services, namely, programs for healthcare personnel about clinical cases and communication practices in the area of Alzheimer disease Medical information services in the field of Alzheimer disease
83.
METHODS OF USING AND COMPOSITIONS INCLUDING AN INCRETIN ANALOG
Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.
The present invention relates to novel compounds comprising novel delivery moieties for delivery of oligonucleotides, which are useful in the treatment of disease, suitably diseases of the liver.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
Aspects of the present disclosure relate to automated skin condition evaluation. A region of interest within image data of a user is identified that is afflicted by a skin or nail condition. A control region that is unafflicted by the condition may similarly be identified, such that a set of chromophore concentrations is generated for the control region. Using the set of chromophore concentrations, an estimated thickness is generated for the region of interest. Thus, it is assumed that the amount of chromophores at the control region are at least approximately the same as the amount of chromophores at the region of interest, such that a difference in coloration between the control region and the region of interest is predominantly the result of a difference in thickness. A skin/nail condition severity metric may thus ultimately be generated for the region of interest using the estimated thickness and/or a surface roughness.
GIP receptor agonists of the present disclosure have anti-emetic properties and therefore can be used to reduce or inhibit the frequency or severity of episodes of nausea or emesis in a patient in need thereof.
1244 are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
The present invention provides compounds of the formula I wherein A, Z, G, R1, R2, and R4 are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
89.
ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
The disclosure relates to the field of diseases caused by a lowered synaptic inhibition, preferably those that are caused by a diminished activity of the potassium (K) / chloride (Cl) cotransporter (KCC2). The disclosure involves oligonucleotides and the use thereof in RNA editing methods in targeting a target adenosine in a codon encoding a phosphorylation site in the KCC2-encoding SLC12A5 pre-mRNA or mRNA, preferably the adenosine in the codon encoding threonine at position 1007 of the KCC2b isoform. Through the editing the threonine is replaced by an alanine, thereby removing the phosphorylation site, and thereby increasing the activity of the KCC2 protein in the process of restoring GABAergic inhibitory tone. The disclosure further relates to oligonucleotides for use in the treatment of chronic pain and epilepsy.
The present invention provides a method for treating or preventing type 2 diabetes in a patient the patient has low HOMA2-B, using tirzepatide as the first line pharmaceutical diabetes treatment. Provided is a method for treating a patient with long-standing type 2 diabetes using tirzepatide and decreased or eliminated basal insulin treatment, wherein such treatment continues for at least 26 weeks.
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
Custom manufacturing of pharmaceuticals and clinical trial materials Pharmaceutical products development; Product research; Research and development in the pharmaceutical and biotechnology fields
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
Custom manufacturing of pharmaceuticals and clinical trial materials Pharmaceutical products development; Product research; Research and development in the pharmaceutical and biotechnology fields
Provided herein are improved methods for producing an Fc-containing protein. The methods generally involve culturing mammalian cells that produce the Fc-containing protein at a first pH setpoint for a first period of time followed by culturing the cell at a second pH setpoint that is higher than the first pH set point for a second period of time.
The disclosure relates generally to biology and medicine, and more particularly it relates to compounds acting as half-life (t½)-extending moieties for use with therapeutics, especially for improving t½ of biological-based therapeutics (i.e., biotherapeutics or biologics). The disclosure further relates to fusions and conjugates that include one or more of the compounds acting as t½-extending moieties, as well as pharmaceutical compositions including the same and their use in treating various conditions, diseases or disorders.
The present disclosure relates to PD-1 agonist antibodies and methods and uses of anti-human PD-1 agonist antibodies for the treatment of inflammatory and/or autoimmune skin diseases. Also provided are doses and dosing regimens for the methods and uses of anti- human PD-1 agonist antibodies for the treatment of inflammatory and/or autoimmune skin diseases such as psoriasis or atopic dermatitis.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Provided herein are improved methods for producing an Fc-containing protein. The methods generally involve culturing mammalian cells that produce the Fc-containing protein at a first pH setpoint for a first period of time followed by culturing the cell at a second pH setpoint that is higher than the first pH set point for a second period of time.
Provided herein are polymorphs of (2E)-3-fluoro-2-({[2-(4-methoxypiperidin-1-yl)pyrimidin-5 -yl]oxy} methyl)prop-2-en-1-aminium 4-methylbenzenesulfonate, compositions thereof, methods of preparation thereof, and methods of use thereof.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07C 309/30 - Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
100.
METHODS FOR THE PREPARATION OF SSTR4 AGONISTS AND SALTS THEREOF
RSrNRSrNN-(2-(1-Methyl-1H-indazol-3-yl)propan-2-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide adipate. Methods of treatment of pain, such as osteoarthritic, neuropathic, and lower back pain through the administration of certain SSTR4 agonists and pharmaceutically acceptable salts thereof.
C07D 209/52 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
